Sector News

Bayer’s finerenone hits targets in diabetes/kidney disease trial

July 13, 2020
Life sciences

Bayer’s finerenone has hit key targets in a late-stage trial assessing its safety and efficacy in patients with chronic kidney disease (CKD) and type 2 diabetes.

Data from the Phase III FIDELIO-DKD renal outcomes study show that the drug significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care.

Finerenone also lowered the risk of a composite of time to first occurrence of CV death, non-fatal myocardial infarction, non-fatal stroke or heart failure hospitalisation, thereby by also meeting secondary targets.

Finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor antagonist to show renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes, according to the firm.

Bayer said it will discuss the data with health authorities with a view to submitting a marketing application in this setting.

By: Selina McKee

Source: Pharma Times

comments closed

Related News

September 26, 2021

Lonza invests to expand drug product development and manufacturing services in Switzerland

Life sciences

Lonza will invest to expand its drug product manufacturing network in Switzerland. The investment will include installation of a new aseptic fill and finish line in Stein and the expansion of Drug Product Services in Basel. The expansion adds new capabilities to support clinical and commercial manufacturing and enhances existing drug product service offering in Basel and Visp.

September 26, 2021

Repairing heart damage by transiently turning back the clock

Life sciences

Partial reprogramming of adult heart cells to a fetal-like state could help repair heart damage following cardiac injury or disease, scientists at the Max Planck Institute for Heart and Lung Research showed in mice. 

September 26, 2021

Merck women’s health spinoff Organon debuts first awareness campaign, taking on unplanned pregnancy

Life sciences

When Merck’s women’s health spinoff Organon launched in June, it promised to listen to—and amplify—women’s voices on overlooked health concerns. Now, the company is getting specific. Organon hopes to ignite a conversation about an issue that affects 121 million women around the world every year.

Send this to a friend